Advanced Data Science and Artificial Intelligence (AI) Technology Platforms to Accelerate Disease Diagnosis

Our methods of utilizing advanced data science and artificial intelligence (AI) technology to accelerate disease diagnosis, drive product adoption, and maximize therapy adherence have benefited clients across a wide breadth of therapeutic areas.

Clients Include

8 of the Top 10 pharmaceutical drug manufacturers

as well as dozens of midsized and emerging biopharmaceutical companies

Evidence of Our Impact: Case Studies

Analytics-driven approach to medical marketing to drive behavior change and uptake

Using Patient-Finding Analytics to Help Drive Earlier Diagnosis plus

BACKGROUND

SITUATION

Immunology product on the market for 3 years with growth stagnating

Crowded marketplace with 5 competitors

Disease is not optimally managed

CHALLENGES

Increase disease diagnosis rates by 10%

Accelerate product adoption with the appropriate patient types

Improve efficiency and effectiveness of HCP and patient promotion

QUESTIONS

What is the treatment journey for our target patients?

Which clinicians are currently managing undiagnosed patients?

How do we drive improved diagnosis rates?

APPROACH

ANALYZE

What is the treatment journey for our target patients?

•	Mapped clinical journey to understand patient flow and treatment patterns
•	Conducted Orion analytics to identify undiagnosed patients

ASSESS

Which clinicians are currently managing undiagnosed patients?

•	Mapped undiagnosed and diagnosed patients to providers currently managing them
•	Prioritized providers based on undiagnosed patient volume, specialty, as well as frequency and recency of interaction

ACTION

How do we drive improved diagnosis rates?

•	Leveraged insights from Plexus analytics to connect providers currently managing undiagnosed patients with the clinical leaders in their networks who were experts in diagnosing the disease

OUTCOME

Expanded Commercial Potential

•	Found more than 100K undiagnosed patients who were being seen by at least 1 physician
•	Uncovered target patients "hiding in plain sight" (ie, being treated by targets for other conditions)

Improved HCP Promotional Effectiveness

•	Segmented HCPs based on patient volume (diagnosed and undiagnosed), as well as diagnosis rates
•	Drove HCP awareness and education by equipping MSLs with a suite of unbranded tools
•	Collaborated with community through ongoing educational partnerships

Revolutionized Patient Engagement Paradigm

•	Changed paradigm by revealing that 58% of undiagnosed patients were female vs expected 75% male
•	Customized content based on actual patient profiles
•	Launched breakthrough disease education campaign targeting undiagnosed patients

Leveraging Network Mapping and Sentiment Analysis to Establish Leadership in a New Area plus

BACKGROUND

SITUATION

Launching 2 products with indications across 3 hematology indications

Targeted tumor types were all ultra-rare

Client did not have any hematology presence

CHALLENGES

Entrenched competitors have been in the market for 5+ years

Limited internal knowledge of dynamics within hematology

No established relationships with Thought Leaders

QUESTIONS

Who are the key clinical leaders within and across tumor types?

What are their perceptions regarding key brand issues and themes?

Which clinicians should lead our speaker programs?

APPROACH

ANALYZE

Who are the key clinical leaders within and across tumor type?

•	Utilized Plexus analytics and real-world data to identify clinical leaders for each tumor type
•	Leveraged CMS open payments data to understand current industry relationships

ASSESS

What are their perceptions regarding key brand issues and themes?

•	Leveraged natural language processing to determine sentiment (Positive, Negative, and Neutral) at a topic level for each thought leader

ACTION

Which clinicians should lead our speaker programs?

•	Integrated insights from Acuity and Plexus to qualify, profile, and sort speakers based on academic leadership, clinical influence, and CMS data institutional restrictions, including prior speaker and consulting engagements

OUTCOME

Established Footprint

•	Recommended engagement with 99 new clinical leaders
•	Medical and commercial teams partnered to review and prioritize clinicians in order to build leadership in market space

Deepened Market Understanding

•	Gained baseline understanding of clinical leader attitudes across 10 key issues
•	Tracked evolution of attitudes to assess market dynamics and impact of messaging

Exceeded Product Uptake Expectations

•	Achieved 40% new-patient share for first approved indication within one year

Launching a Regional Marketing Team by Leveraging Predictive Analytics plus

BACKGROUND

SITUATION

Highly successful oncology drug in a competitive market looking to grow market share

Upcoming launch of new customer-facing team who will be accountable for thought leader (TL) engagement

Needed to identify TLs who strike a balance with respect to clinical, academic, and industry leadership

CHALLENGES

Ensuring stakeholders within the company were aligned on vision for the new team

Differentiating the team from other TL-facing contacts (sales reps, account managers, etc)

Identifying the right mix of TLs to optimize commercial needs

QUESTIONS

Who are the clinical and academic leaders and how are they connected to other HCPs?

Who are the TLs that should be prioritized for engagement?

How do we structure the new team so that it benefits both the customers and the company?

APPROACH

ANALYZE

Who are the clinical and academic leaders, and how are they connected to other HCPs?

•	Conducted Acuity and Plexus analytics to identify academic and clinical leaders and their respective networks

ASSESS

Who are the TLs that should be prioritized for engagement?

•	Integrated Acuity and Plexus academic and clinical analyses to create diverse list of TLs with singular view
•	Identified weighted and normalized scale of academic, clinical, and industry engagement to create TL score of 1-100
•	Worked with regional marketing leads to select TLs from a ranked list
•	Captured detailed profiles of TLs in Acuity stakeholder management system to support focused engagement

ACTION

How do we structure the new team so that it benefits both the customers and the company?

•	Created actionable recommendations for team based on strategic imperatives and stakeholder interviews
•	Developed a concise "walking deck" to clearly present the role to internal stakeholders

OUTCOME

•	Identified, selected, and profiled 120 TLs with diverse academic,clinical, and industry experience
•	Educated Internal stakeholders on regional marketing team's strategy, ensuring a smooth launch for the team
•	Significantly increased engagement and advocacy from TLs

Advanced Data Science and Artificial Intelligence (AI) Technology Platforms to Accelerate Disease Diagnosis

OUR SOLUTIONS

Purpose-Driven RWD Solutions

HOW WE DO IT

Evidence of Our Impact: Case Studies

OUR LEADERSHIP

Advanced Data Science and Artificial Intelligence (AI) Technology Platforms to Accelerate Disease Diagnosis

OUR SOLUTIONS

Purpose-Driven RWD Solutions

HOW WE DO IT

Evidence of Our Impact: Case Studies

OUR LEADERSHIP

SOCIAL

81qd

Recent Activity